Beta-defensin 134

Also known as: Defensin, beta 134, DEFB134, Q4QY38

Beta-defensin 134 (DEFB134) is a member of the beta-defensin family of antimicrobial peptides, characterized by a conserved beta-sheet structure stabilized by three disulfide bridges. Its proposed mechanism of action involves direct interaction with bacterial cell membranes, leading to membrane disruption and subsequent cell lysis. This cationic peptide is thought to target negatively charged microbial membranes, a common feature among defensins, though its specific binding affinity and selectivity remain uncharacterized due to limited experimental data. As of current literature, no peer-reviewed research findings have been published on DEFB134. Its status as an experimental peptide suggests it has been identified through genomic or transcriptomic analyses, but functional studies, including antimicrobial activity assays or in vivo models, have not been conducted. The absence of PubMed references indicates that its antibacterial properties are inferred from homology to other beta-defensins rather than direct evidence. Given the lack of experimental validation, the clinical relevance of beta-defensin 134 is entirely speculative. It may represent a candidate for future antimicrobial development, particularly in the context of rising antibiotic resistance, but no therapeutic applications can be considered without further investigation. For research purposes only — not medical advice.

Key data

Mechanism of action

Has antibacterial activity

Frequently asked questions

Related peptides